Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment

Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment
Innovation Pharmaceuticals is planning a first clinical trial of an oral formulation of Brilacidin as a treatment for ulcerative colitis (UC), one of the most common types of inflammatory bowel disease (IBD). Brilacidin is a synthetic small molecule that belongs to a new class of compounds known as defensin-mimetics. It is structurally similarity to proteins naturally produced in the body that fend off bacteria and other microbes. Preclinical and clinical data have demonstrated that this compound holds strong immunomodulatory, anti-inflammatory, and anti-infective properties. "With pharmaceutical industry interest in defensin-based therapies intensifying ... the planned upcoming UC program trial couldn’t be happening at a better time — an opportunity to further develop Brilacidin’s platform potential," Leo Ehrlich, CEO of Innovation, said in a press release. "Defensins function in a broad immunomodulatory capacity, exhibiting beneficial characteristics, both anti-inflammatory and anti-infective. Defensin-based therapies thus have the unique potential to treat a wide array of diseases," Ehrlich added. "Brilacidin is the only defensin-based drug candidate in later-stage clinical testing — now anchored by successful results in acute bacterial skin and skin structure infection, oral mucositis,
Subscribe or to access all post and page content.